Results 41 to 50 of about 133,403 (307)

Point mutations of the P53 gene, human hepatocellular carcinoma and aflatoxins [PDF]

open access: yes, 1993
The tumor suppressor p53 exerts important protective functions towards DNA-damaging agents. Its inactivation by allelic deletions or point mutations within the P53 gene as well as complex formation of wildtype p53 with cellular or viral proteins is a ...
Alexander L. Gerbes   +40 more
core   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

Radiation induced esophageal adenocarcinoma in a woman previously treated for breast cancer and renal cell carcinoma [PDF]

open access: yes, 2012
BACKGROUND: Secondary radiation-induced cancers are rare but well-documented as long-term side effects of radiation in large populations of breast cancer survivors. Multiple neoplasms are rare.
Amina Mohtaram   +11 more
core   +1 more source

FGFR Like1 drives esophageal cancer progression via EMT, PI3K/Akt, and notch signalling: insights from clinical data and next‐generation sequencing analysis

open access: yesFEBS Open Bio, EarlyView.
Clinical analysis reveals significant dysregulation of FGFRL1 in esophageal cancer (EC) patients. RNAi‐coupled next‐generation sequencing (NGS) and in vitro study reveal FGFRL1‐mediated EC progression via EMT, PI3K/Akt, and Notch pathways. Functional assays confirm its role in tumor growth, migration, and invasion.
Aprajita Srivastava   +3 more
wiley   +1 more source

Domain associated with zinc fingers‐containing NF90‐NF45 complex inhibits m6A modification of primary microRNA by suppressing METTL3/14 activity

open access: yesFEBS Open Bio, EarlyView.
NF90–NF45 functions as a negative regulator of methyltransferase‐like 3/14 (METTL3/14)‐mediated N6‐methyladenosine (m6A) modification on primary microRNAs (pri‐miRNAs). NF90–NF45 binds to anti‐oncogenic pri‐miRNAs and inhibits their m6A modification, thereby suppressing the biogenesis of anti‐oncogenic miRNAs.
Takuma Higuchi   +6 more
wiley   +1 more source

Correlation between sarcopenia and esophageal cancer: a narrative review

open access: yesWorld Journal of Surgical Oncology
Background In recent years, the research on the relationship between sarcopenia before and after the treatment of esophageal cancer, as well as its impact on prognosis of esophageal cancer, has increased rapidly, which has aroused people’s attention to ...
Shenglan Li   +5 more
doaj   +1 more source

Respiratory muscle strength of patients with esophagus and stomach neoplasms

open access: yesFisioterapia em Movimento
Introduction: In cancer patients, the reduced food intake causes weight loss and promotes protein-calorie malnutrition. This results in loss of lean body mass, which affects both skeletal muscles and respiratory muscles.
Evelyn Aline Boscolo Ruivo   +4 more
doaj   +1 more source

Esophageal pulmonary fistula – a rare complication of radiation therapy: a case report

open access: yesJournal of Medical Case Reports, 2018
Background Esophageal respiratory fistulae are abnormal communications between the esophagus and the respiratory system. They are either congenital or acquired.
Laetitia Buemi   +4 more
doaj   +1 more source

Breast radiation-associated secondary malignancies: A review

open access: yesClinical Surgical Oncology, 2023
Secondary malignancies are a late complication of radiation treatment for primary cancer through DNA damage. Specifically after breast cancer radiation, a number of tissues are vulnerable to radiation damage and have increased risk for developing ...
Sarah Poland   +3 more
doaj   +1 more source

Natural history of patients with non cirrhotic portal hypertension: Comparison with patients with compensated cirrhosis [PDF]

open access: yes, 2018
Background. The knowledge of natural history of patients with portal hypertension (PH) not due to cirrhosis is less well known than that of cirrhotic patients. Aim.
Aprile, Francesca   +7 more
core   +1 more source

Home - About - Disclaimer - Privacy